Spots Global Cancer Trial Database for Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Official Title: Phase I/II Study of Nivolumab in Combination With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Study ID: NCT03681561
Conditions
Study Description
Brief Summary: This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Illinois Cancer Center, Chicago, Illinois, United States
Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
University of Minnesota, Minneapolis, Minnesota, United States
University of Wisconsin, Madison, Wisconsin, United States
Contact Details
Name: Veronkia Bachanova
Affiliation: University of Minnesota
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
